[{"NetIncomeLossConverted_1_Q1_USD":17371000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":181772000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_1_Q1_USD":113512000.0,"EarningsPerShareDiluted_1_Q1_USD":0.09,"CommonStockSharesOutstanding_0_Q1_shares":182670614.0,"StockholdersEquity_0_Q1_USD":4162010000.0,"RevenuesConverted_1_Q1_USD":486030000.0,"Assets_0_Q1_USD":5805053000.0,"CommonStockSharesConverted_0_Q1_shares":182670614.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":184365000.0,"EarningsPerShareBasic_1_Q1_USD":0.1,"Ticker":"BMRN","CIK":"1048477","name":"BIOMARIN PHARMACEUTICAL INC","OfficialName":"BioMarin Pharmaceutical Inc. Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"14899091235.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210430"}]